UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000024229 |
|---|---|
| Receipt number | R000027816 |
| Scientific Title | Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure |
| Date of disclosure of the study information | 2016/10/01 |
| Last modified on | 2017/04/03 09:25:22 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Acronym
Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Scientific Title
Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Scientific Title:Acronym
Effects of a Granule Containing Fermented Soba Extract (neo-FBS) on the Decrease of Blood Pressure
Region
| Japan |
Condition
Condition
Normal high blood pressure or Grade 1 hypertension
Classification by specialty
| Adult |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
This study examine effect of a granule containing fermented soba extract (neo-FBS) on the decrease of blood pressure.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Blood pressure, pulsation (Week 0, Week 4, Week 8, Week 12)
Key secondary outcomes
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Double blind -all involved are blinded
Control
Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
3
Purpose of intervention
Treatment
Type of intervention
| Food |
Interventions/Control_1
Oral ingestion of the test products containing fermented soba extract (2g per a day; 8 weeks)
Interventions/Control_2
Oral ingestion of the test products containing fermented soba extract (2g per a day; 8 weeks)
Interventions/Control_3
Oral ingestion of the placebo not containing fermented soba extract (2g per a day; 8 weeks)
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 30 | years-old | <= |
Age-upper limit
| 70 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1) Males and females aged 30-70 years
2) Individuals who are healthy and are not receiving treatment of disease
3) Individuals who are high normal blood pressure (SBP: 130-140mmHg and/or DBP: 85-90mmHg) and Grade 1 hypertension (SBP: 140-160mmHg and/or DBP: 90-100mmHg)
4) Individuals whose written informed consent has been obtained
5) Individuals judged appropriate for the study by the principal
Key exclusion criteria
1) Individuals who are sensitive to a food containing soba and test product or other foods, and medical products
2) Individuals who are receiving treatment of serious hepatopathy, kidney damage, heart disease and hematological disease
3) Individuals who have a habit of smoking
4) Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 months or will ingest those foods during the test period
5) Individuals who participated in other clinical studies in the past three months
6) Individuals who are or are possibly pregnant, or are lactating
Target sample size
54
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Toru Sahashi |
Organization
SBS Shizuoka Health Promotion Center
Division name
Deputy Director
Zip code
Address
3-1-1, Toro Shizuoka Suruga-ku, Shizuoka
TEL
054-282-1109
dokku@sbs-smc.or.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Masanori Inoue |
Organization
Laboratory of Cell Applied Technologies, Co
Division name
Director
Zip code
Address
2-16-1 Sugao, Miyamae-ku, Kawasaki 216-8512 Japan
TEL
044-979-1622
Homepage URL
info@l-cat.co.jp
Sponsor or person
Institute
Laboratory of Cell Applied Technologies, Co
Institute
Department
Personal name
Funding Source
Organization
Daiwa Pharmaceutical Co.,Ltd.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 10 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2016 | Year | 09 | Month | 04 | Day |
Date of IRB
Anticipated trial start date
| 2016 | Year | 10 | Month | 22 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2016 | Year | 09 | Month | 30 | Day |
Last modified on
| 2017 | Year | 04 | Month | 03 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027816
